News|Articles|March 9, 2024

Mood Disorders in Psychiatric Times

Take a look back at our recent coverage relating to our March content theme.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe

Related Content

Xanomeline/Trospium in Treatment-Refractory Bipolar I Disorder With Psychosis: A Case Report of Rapid Agitation Control and Functional Improvement

ByPragyan Sharma, MD, MSc,Samara White, PharmD,Ranel Troy Santos, PharmD, BCPP

August 5th 2026

Effective Prescription of Exercise for the Treatment of Depression and Anxiety

ByPrerna Gait, MD

August 4th 2026

What Does Interventional Psychiatry Actually Mean? Reframing Non-Standard Treatments for Depression

ByLara Shirikjian, MD

July 31st 2026

What's New in Psychiatric Treatment? Highlights From the 2026 Southern California Psychiatry Conference

ByJessica Walters

July 30th 2026

From Fibromyalgia to Depression: TNX-102 Sublingual Cyclobenzaprine Trials for MDD

ByGregory Sullivan, MD

July 30th 2026

Latest CME

Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

In-Person Event

Jersey City Psychiatry

October 2-3, 2026

Register now!

Video

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Video

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

Video

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Mood Disorders in Psychiatric Times

Related Content

Xanomeline/Trospium in Treatment-Refractory Bipolar I Disorder With Psychosis: A Case Report of Rapid Agitation Control and Functional Improvement

Effective Prescription of Exercise for the Treatment of Depression and Anxiety

What Does Interventional Psychiatry Actually Mean? Reframing Non-Standard Treatments for Depression

What's New in Psychiatric Treatment? Highlights From the 2026 Southern California Psychiatry Conference

From Fibromyalgia to Depression: TNX-102 Sublingual Cyclobenzaprine Trials for MDD

Latest CME

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jersey City Psychiatry

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Trending on Psychiatric Times

FAQ: What Clinicians Need to Know About Postpartum Psychosis

Psychiatry Mid-Year Market Update 2026: Persistent Demand, Widening Valuation Gap, and Workforce/Regulatory Realities

Interdisciplinary Consensus Guidelines on Stuttering (Childhood-Onset Fluency Disorder): Addressing Issues in Diagnosis, Treatment, and Unmet Needs

New in Narcolepsy: Pharmacology Updates

Morning Rounds: News From August 3-9